DAY 1 - Sunday, June 26, 2011

Welcome

Greetings from the American Diabetes Association’s 71^st Scientific Sessions

The editorial staff of Medical Economics brings you daily coverage of breaking news, the latest research findings, and reports of interest to the readers of Medical Economics, Drug Topics, Formulary, and Contemporary OB/GYN.

Our four-day coverage of this year’s American Diabetes Association’s 71st Scientific Sessions begins today and includes the results of major clinical trials and ongoing news and information of interest to clinicians who treat type 1 and 2 diabetes.

NEW RESEARCH

Adding saxagliptin to metformin results in better glycemic control vs. uptitrating metformin dose

Vivian Fonseca, MD

Adding saxagliptin to metformin instead of increasing the dose of metformin results in significant improvement in levels of hemoglobin 1c (HbA_1c), fasting plasma glucose, and postprandial glucose in patients with type 2 diabetes with inadequate glycemic control despite being on a stable dose of metformin, according to the results of a randomized open-label study.
» MORE

EMERGING THERAPIES

High-dose salsalate improves fasting glucose; holds potential for preventing type 2 diabetes

Targeting inflammation with salicylate therapy to inhibit nuclear factor κB (NF- κB) activity may represent a novel strategy to prevent diabetes, said Peter Reaven, MD.
» MORE

PATIENT MANAGEMENT

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Ying Qiu

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.
» MORE

Bariatric surgery improves CV risk factors, but too many patients stop their cardiac medications

Bariatric surgery improves cardiovascular (CV) risk factors, with glycemia responding the most dramatically following surgery, said Sayeed Ikramuddin, MD. Over the long term, systolic blood pressure (SBP) and low-density lipoprotein (LDL) cholesterol respond less favorably, which may be partially explained by inappropriate cessation of medicines, he said.» MORE

HbA_1c found wanting for diabetes screening in at-risk veterans

Sandra L Jackson

Slightly more than half of all U.S. veterans targeted for diabetes screening had unrecognized diabetes or prediabetes, indicating a need for widespread screening in this population.» MORE

CLINICAL TRIAL RESULTS

Four years on, intensive lifestyle changes yield benefits over standard diabetes care

Four years into a 13-plus-year study, an intensive lifestyle intervention (ILI) for patients with type 2 diabetes mellitus has produced sustained, significant improvements in glycemic control, systolic blood pressure, and high-density lipoprotein (HDL) cholesterol compared with standard diabetes support and education (DSE) programs, reported investigators with the Look AHEAD (Action for Health in Diabetes) trial.
» MORE

Intensive lifestyle intervention sends some diabetes cases into remission

Alain Bertoni, MD

An intensive lifestyle intervention (ILI) for overweight and obese people with type 2 diabetes has induced significantly more remissions of diabetes than standard diabetes education.
» MORE

FDA attempts to promote innovation through guidance and flexibility

Although the regulatory environment in the U.S. has been criticized for stifling pharmaceutical innovation and investment, several targeted Food and Drug Administration (FDA) activities have been designed to support innovation, said Douglas Throckmorton, MD, Deputy Director for Regulator Programs, Center for Drug Evaluation and Research at the FDA.» MORE

Medical Economics is pleased to share this ADA conference coverage with the readers of:

From the conference floor

Exhibit Hall Hours

Sunday, June 26
10 a.m. – 4 p.m.

Monday, June 27
10 a.m. – 2 p.m.

We welcome your feedback!
Please send your comments to:
Medical Economics editorial staff
medec@advanstar.com